The restructuring follows the company's receipt of a letter from the FDA citing "deficiencies" in its approval application for diabetes drug Zynquista.
Howard Chang will take over as chief scientific officer and senior VP of research as the biotech searches for more ways to ...
In buying Westlake-backed Kate Therapeutics, Novartis gets a handful of preclinical gene therapies targeting diseases like ...
Venture capital firms incubate, grow and finance dozens of drug companies each year. Follow the money they channel into the ...
The startup, Pep2Tango, is combining four methods of accelerating weight loss into one medicine in the hopes of developing a ...
President-elect Donald Trump on Friday named Johns Hopkins University surgeon Marty Makary to lead the Food and Drug ...
Built around research by Stanford scientist Carolyn Bertozzi and MIT researcher Jessica Stark, Valora Therapeutics is ...
The company paused testing of one candidate acquired in its April deal for Escient and scrapped another in a blow to its ...
Analysts see Trump’s victory raising the high-profile legislation’s chances of becoming law. But the realities of a lame duck ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback